Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.The Motley Fool • Wednesday
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.The Motley Fool • Monday
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetZacks Investment Research • 10/30/26
Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)Seeking Alpha • 10/29/26
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases24/7 Wall Street • 10/29/26
Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The StockSeeking Alpha • 10/29/26
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 10/28/26
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 2824/7 Wall Street • 10/25/26
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader MarketZacks Investment Research • 10/23/26
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 10/22/26
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026PRNewsWire • 10/21/26
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research • 10/20/26
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsThe Motley Fool • 10/20/26
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2The Motley Fool • 10/20/26
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.The Motley Fool • 10/18/26